Info

Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Company's products are based on the EVadeÔ Ribonuclease Technology which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases. The EVadeÔ Ribonuclease technology is covered by patents acquired by the Company through an exclusive license with the University of Wisconsin. The Company is in the late pre-clinical stages of development of QBI-139 and is expecting to file an Investigational New Drug Application in the first half of 2008. Phase I human clinical trials are expected to begin soon after filing the IND. Second generation products are under development and pre-clinical work is ongoing.